Carlyle Expands Leading Healthcare Franchise with Agreement to Acquire Life Sciences Investment Firm Abingworth
NEW YORK, NY – Global investment firm Carlyle (NASDAQ: CG) announced today that it has agreed to acquire Abingworth, a transatlantic life sciences investment firm with over $2 billion in assets under management (AUM), to bolster Carlyle’s leading global healthcare franchise. This transaction will enable Carlyle to operate across the full risk-return spectrum of life sciences and healthcare investing, from venture capital to buyouts, and to continue Carlyle’s long-standing efforts to be an important part of the solution in healthcare.
Abingworth, with a local presence across the three key biotech hubs of London, Boston, and the San Francisco Bay Area, adds to Carlyle a specialized and experienced team of over 20 investment professionals and advisors with deep scientific backgrounds and an established track record investing across early- and late-stage biotech companies to address significant, growing demand.
Since its founding in 1973, Abingworth has successfully deployed $3 billion of equity behind 179 life sciences companies through 14 dedicated life sciences funds. During this time, 73 portfolio companies have transitioned onto the public markets through initial public offerings (IPOs) and 46 companies have undergone a merger or acquisition. Importantly, 26 new medicines, developed by companies funded by and built by Abingworth, have been approved by the US Food & Drug Administration in the past nine years.
In addition to early- and development-stage investing, Abingworth is a pioneer of the clinical co-development strategy, an aligned and efficient approach to partnering with pharma and biotech companies to help them finance and develop late-stage therapeutic assets in an accelerated manner.
To further scale this strategy, Carlyle and Abingworth are forming Launch Therapeutics (“Launch Tx”), an operating company that will seek to partner with biotech and biopharma companies on funding and development of best‐in‐class late‐stage clinical assets to bring life‐saving therapies to market better, faster, and cheaper. Launch Tx’s objective is to bring forth regulatory, medical, and clinical operations expertise to eliminate inefficiencies in clinical development and accelerate path to market. Launch Tx will be led by industry veteran Anshul Thakral, former Chief Commercial Officer of PPD and a current Carlyle Operating Executive and Abingworth Venture Partner.
“The COVID-19 pandemic shed light on the increased need for expertise and access to capital to fund the development and commercialization of innovative healthcare and life sciences solutions in the years to come,” said Steve Wise, Carlyle’s Global Head of Healthcare. “We’re excited to partner with the world-class team at Abingworth to expand upon Carlyle’s deep global healthcare expertise to invest in transformative businesses across the entire life sciences landscape.”
“We strongly believe that the innovative life sciences investment franchise of Abingworth, the resources and global network of Carlyle, and the operational expertise of Anshul Thakral and other seasoned healthcare professionals at Launch Tx will position us to be a critical partner to pharma and biotech companies seeking capital and partnership to advance clinical programs,” added Joe Bress, a Managing Director on Carlyle’s Healthcare team.
“The combination of Abingworth and Carlyle creates an incredible force within the global healthcare investment ecosystem,” said Kurt von Emster, Managing Partner at Abingworth.
“We’re proud of Abingworth’s history of partnering with entrepreneurs to create companies that have a significant impact on patients’ lives and we’re incredibly excited about what the future will hold as we continue to grow our strong franchises in life sciences venture capital and later-stage clinical co-development as part of Carlyle,” said Tim Haines, Chair and Managing Partner at Abingworth.
“We see a strong market need for a clinical development company that can bring access to capital, global resources and deep operational expertise to biotech and biopharma companies looking to advance therapeutic candidates through clinical trials and regulatory approval,” said Anshul Thakral, CEO of Launch Tx. “I’m thrilled to partner with the entire Carlyle and Abingworth organizations to form Launch Therapeutics.”
Today’s announcement demonstrates an extension of Carlyle’s long-term global commitment to leadership in healthcare in which it has invested over $22 billion across buyout and growth equity since inception, including in transformative pharma and life sciences businesses such as PPD, Adicon, Curia, Piramal, Saama, SeQuent, TriNetX, and Unchained Labs.
Carlyle’s acquisition of Abingworth is subject to customary closing conditions and is expected to close in 2022. Terms of the transaction were not disclosed.
Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With $301 billion of assets under management as of December 31, 2021, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs nearly 1,850 people in 26 offices across five continents. Further information is available at www.carlyle.com. Follow Carlyle on Twitter @OneCarlyle.
Abingworth is a leading transatlantic life sciences investment firm with over $2 billion under management. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in over 179 life science companies, leading to 46 M&As and 73 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. www.abingworth.com
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, statements related to our expectations, estimates, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts, including statements with respect to the proposed acquisition of the CBAM assets; the transaction’s effects on AUM, Fee Related Earnings and other performance metrics and the timing of such effects; the issuance of new equity securities and the availability of cash on hand to fund the transaction; and the expected timing of closing. You can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements including, but not limited to, failure to complete the acquisition or otherwise realize its anticipated benefits within the expected timeframes, unforeseen liabilities or integration and other costs of the acquisition and timing related thereto, and those described under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 10, 2022, as such factors may be updated from time to time in our periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law.
+1 (212) 813-4839
Mark Swallow or Eleanor Perkin (MEDiSTRAVA Consulting)
+44 (0)203 928 6900